Continue to learn
In December 2025, Maxvax announced the completion of a D+ round financing totaling several hundred million RMB. This round was jointly invested by Chengdu Sci-Tech Investment, Shenzhen Capital Group, Guosheng Capital, and Linchuang Blue Bay. The funds raised will be primarily used to support the launch and commercialization of the recombinant herpes zoster (shingles) vaccine, the Phase III clinical trials of the recombinant respiratory syncytial virus (RSV) vaccine, as well as the preclinical development and international cooperation of multiple innovative vaccine pipelines.
more >On October 22, 2025, Maxvax Biotechnology Co., Ltd. (“Maxvax”) announced that its wholly owned subsidiary, Shanghai Maxvax Biotechnology Co., Ltd., has officially initiated the Phase III clinical trial for its Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell). The first group of participants has been successfully enrolled in Xianning, Hubei Province.
more >Maxvax Biotechnology LLC (USA) recently announced that it has received funds from the Gates Foundation to support the development of its recombinant respiratory syncytial virus (RSV) maternal vaccine candidate.
more >Recently, the registration application for the Adjuvanted Recombinant Herpes Zoster Vaccine (CHO Cell) independently developed by Shanghai Maxvax Biotechnology has been officially accepted by Chinese national regulatory authorities(Acceptance No. CXSS2500114).
more >Maxvax announced on October 31, 2025 the successful completion of its Series D financing round, raising over RMB 400 million. This round was jointly invested by IDG Capital, Shenzhen Capital Group (SCGC), and Ruipu Pharma. The funds will primarily support the clinical trials and commercialization preparation of Maxvax’s recombinant shingles (herpes zoster) vaccine, the Phase III clinical trial of its recombinant respiratory syncytial virus (RSV) vaccine, and preclinical research for multiple innovative vaccine candidates and international collaborations.
more >On January 23rd, Maxvax announced the successful enrollment and vaccination of all subjects in the Phase II clinical trial for its recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) at the Disease Control and Prevention Center in Liangyuan District, Shangqiu City, Henan Province. This marks the first domestic RSV vaccine to enter Phase II clinical trials in China.
more >
In December 2025, Maxvax announced the completion of a D+ round financing totaling several hundred million RMB. This round was jointly invested by Chengdu Sci-Tech Investment, Shenzhen Capital Group, Guosheng Capital, and Linchuang Blue Bay. The funds raised will be primarily used to support the launch and commercialization of the recombinant herpes zoster (shingles) vaccine, the Phase III clinical trials of the recombinant respiratory syncytial virus (RSV) vaccine, as well as the preclinical development and international cooperation of multiple innovative vaccine pipelines.
more >
Maxvax Biotechnology LLC (USA) recently announced that it has received funds from the Gates Foundation to support the development of its recombinant respiratory syncytial virus (RSV) maternal vaccine candidate.
more >
Maxvax announced on October 31, 2025 the successful completion of its Series D financing round, raising over RMB 400 million. This round was jointly invested by IDG Capital, Shenzhen Capital Group (SCGC), and Ruipu Pharma. The funds will primarily support the clinical trials and commercialization preparation of Maxvax’s recombinant shingles (herpes zoster) vaccine, the Phase III clinical trial of its recombinant respiratory syncytial virus (RSV) vaccine, and preclinical research for multiple innovative vaccine candidates and international collaborations.
more >
On October 22, 2025, Maxvax Biotechnology Co., Ltd. (“Maxvax”) announced that its wholly owned subsidiary, Shanghai Maxvax Biotechnology Co., Ltd., has officially initiated the Phase III clinical trial for its Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell). The first group of participants has been successfully enrolled in Xianning, Hubei Province.
more >
Recently, the registration application for the Adjuvanted Recombinant Herpes Zoster Vaccine (CHO Cell) independently developed by Shanghai Maxvax Biotechnology has been officially accepted by Chinese national regulatory authorities(Acceptance No. CXSS2500114).
more >
On January 23rd, Maxvax announced the successful enrollment and vaccination of all subjects in the Phase II clinical trial for its recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) at the Disease Control and Prevention Center in Liangyuan District, Shangqiu City, Henan Province. This marks the first domestic RSV vaccine to enter Phase II clinical trials in China.
more >